Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Background The site of action of the 5-fluorouracil (5-FU) antitumor effect has been explicated in recent years. Many studies have investigated enzymes involved in 5-FU metabolism in attempts to predict this effect, and a correlation of enzyme activity with the 5-FU drug sensitivity test has been reported. The aim of this study was to identify the biochemical response determinants of 5-FU. Additionally, we aimed to clarify the association between cell proliferative activity and the response to 5-FU of colorectal cancer.Methods Our research subjects were 54 patients with colorectal carcinoma who had undergone operations between August 1999 and July 2001 in our department. Assays of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), and orotate phosphoribosyltransferase (OPRT) activities in colorectal carcinoma tissue and assays of 5-FU sensitivity by the collagen gel droplet embedded culture drug sensitivity test (CD-DST) were conducted to investigate the relationships between each enzyme activity and 5-FU sensitivity. In addition, the proliferative activity of cancer cells was evaluated with Ki-67 antibody, and the relationship of this activity to each enzyme activity and 5-FU sensitivity were investigated.Results 5-FU sensitivity was high in the low-TS-activity group and in the high-OPRT-activity group. Cancers with high cell proliferative activity showed good sensitivity to 5-FU, and TS and OPRT activities were high in such cancers.Conclusion The results suggest that OPRT activity can predict sensitivity to 5-FU, and high OPRT activity may cause good 5-FU sensitivity in cancers with high cell proliferative activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been proven that the lower expression of these metabolic enzymes is associated with 5-FU resistance in CRC patients [6,7,8].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [6]
Citations
Cites
Salonga, D. S., Danenberg, K. D., Johnson, M. R., Metzger, R., Groshen, S. G., Tsao-Wei, D. D., Lenz, H.-J., Leichman, C. G., Leichman, L., Diasio, R. B., et al. (2000) · PubMed · Cited by 829
Johnston, P. G., Lenz, H.-J., Leichman, C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V., & Leichman, L. (1995) · PubMed · Cited by 672
Diasio, R. B., Beavers, T. L., & Carpenter, J. T. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113308 · Cited by 503
Johnston, P. G., Fisher, E. R., Rockette, H. E., Fisher, B., Wolmark, N., Drake, J. C., Chabner, B. A., & Allegra, C. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2640 · Cited by 405
Chemotherapy for Colorectal Cancer
Wood, A. J. J., & Moertel, C. G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199404213301608 · Cited by 372
Etienne, M. C., Chéradame, S., Fischel, J. L., Formento, P., Dassonville, O., Renée, N., Schneider, M., Thyss, A., Demard, F., & Milano, G. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1663 · Cited by 281 · cited 1×
“Previous investigations of TS mainly measured protein levels; however, the present investigation measured TS enzyme activity by means of a tritium release method.(7) The tissue sample was homogenized in 50mmol/l TrisHCl (pH 7.”
MethodBeck, A., Etienne, M. C., Chéradame, S., Fischel, J. L., Formento, P., Renée, N., & Milano, G. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00216-r · Cited by 270
Aschele, C., Debernardis, D., Casazza, S., Antonelli, G., Tunesi, G., Baldo, C., Lionetto, R., Maley, F., & Sobrero, A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1760 · Cited by 203
Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.
Spears, C. P., Gustavsson, B. G., Berne, M., Frösing, R., Bernstein, L., & Hayes, A. A. (1988) · PubMed · Cited by 138
Cascinu, S., Aschele, C., Barni, S., Debernardis, D., Baldo, C., Tunesi, G., Catalano, V., Giordani, P., Baldelli, A. M., & Catalano, G. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)80648-0 · Cited by 122
Cited by
Blondy, S., David, V., Verdier, M., Mathonnet, M., Perraud, A., & Christou, N. (2020) · Cancer Science · doi:10.1111/cas.14532 · Cited by 507
Boyer, J., McLean, E. G., Aroori, S., Wilson, P., McCulla, A., Carey, P. D., Longley, D. B., & Johnston, P. G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0362 · Cited by 229
“Recent clinical data also suggest that OPRT activity can predict sensitivity to 5-FU in CRC patients, with high levels correlating with increased sensitivity (38, 39).”
BackgroundDrug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success
Ashique, S., Bhowmick, M., Pal, R., Khatoon, H., Kumar, P., Sharma, H., Garg, A., Kumar, S., & Das, U. (2024) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2024.100114 · Cited by 139
Ichikawa, W., Uetake, H., Shirota, Y., Yamada, H., Takahashi, T., Nihei, Z., Sugihara, K., Sasaki, Y., & Hirayama, R. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601335 · Cited by 129
“Recently, in studies using human colorectal cancer tissues, a higher OPRT enzyme activity was observed in 5-FU-sensitive tissues than nonsensitive ones in in vitro chemosensitivity test (Isshi et al, 2002; Fujii et al, 2003).”
BackgroundResultPharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years
Panczyk, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9775 · Cited by 122
Genetic factors influencing Pyrimidine-antagonist chemotherapy
Maring, J. G., Groen, H. J. M., Wachters, F. M., Uges, D. R. A., & de Vries, E. G. E. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500320 · Cited by 122
“High OPRT activity was associated with good in vitro sensitivity to 5-FU, measured by Collagen Gel Droplet Embedded Culture Drug Sensitivity test, Fluoresceine Diacetate Assay or Histoculture Drug Response Assay, in human colorectal cancer tissues [61,62].”
BackgroundGmeiner, W. H., & Okechukwu, C. C. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.136 · Cited by 131
Showalter, S. L., Showalter, T. N., Witkiewicz, A., Havens, R., Kennedy, E. P., Hucl, T., Kern, S. E., Yeo, C. J., & Brody, J. R. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.7.6181 · Cited by 98
Wada, Y., Yoshida, K., Suzuki, T., Mizuiri, H., Konishi, K., Ukon, K., Tanabe, K., Sakata, Y., & Fukushima, M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21879 · Cited by 87
Matsuyama, R., Togo, S., Shimizu, D., Momiyama, N., Ishikawa, T., Ichikawa, Y., Endo, I., Kunisaki, C., Suzuki, H., Hayasizaki, Y., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21843 · Cited by 78
“Recent studies using in vitro chemosensitivity tests have revealed that OPRT enzyme activity is higher in 5-FU-sensitive tissues than in nonsensitive ones.(30) Ichikawa et al.”
BackgroundIchikawa, W., Takahashi, T., Suto, K., Sasaki, Y., & Hirayama, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2665 · Cited by 71
Ichikawa, W. (2006) · Gastric Cancer · doi:10.1007/s10120-006-0373-8 · Cited by 63
“Higher levels of OPRT expression were associated with greater sensitivity to 5-FU [68,69].”
BackgroundNakano, J., Huang, C., Liu, D., Masuya, D., Nakashima, T., Yokomise, H., Ueno, M., Wada, H., & Fukushima, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603297 · Cited by 61
“However, there were only a few clinical studies on the simultaneous evaluations of these biomarkers to evaluate 5-FU sensitivity (Isshi et al, 2002; Fujii et al, 2003; Ichikawa et al, 2003a).”
BackgroundMethodHamaguchi, J., Nakagawa, H., Takahashi, M., Kudo, T., Kamiyama, N., Sun, B., Oshima, T., Sato, Y., Deguchi, K., Todo, S., et al. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-58 · Cited by 45
“This expression profile corresponds to that in previous reports showing that TS inactivates 5-FU, and OPRT activates 5-FU function [ 35- 37 ].”
Yanamoto, S., Iwamoto, T., Kawasaki, G., Yoshitomi, I., Baba, N., & Mizuno, A. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.10.019 · Cited by 43
Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma
Wang, J., Liu, W., Zhao, Q., Qi, Q., Lu, N., Yang, Y., Nei, F.-F., Rong, J., You, Q., & Guo, Q. (2008) · Toxicology · doi:10.1016/j.tox.2008.11.014 · Cited by 39
Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma
Mizutani, Y., Wada, H., Fukushima, M., Yoshida, O., Nakanishi, H., Li, Y. N., & Miki, T. (2004) · Cancer · doi:10.1002/cncr.11955 · Cited by 37
“high OPRT activity and that high OPRT activity in colon carcinoma predicts high sensitivity to 5-FU.(28,29)”
BackgroundShimoda, M., Kubota, K., Shimizu, T., & Katoh, M. (2015) · British journal of surgery · doi:10.1002/bjs.9775 · Cited by 34
Pharmacogenomic Characterization of Cytotoxic Compounds from Salvia officinalis in Cancer Cells
Kadioglu, O., & Efferth, T. (2015) · Journal of Natural Products · doi:10.1021/np501007n · Cited by 36
Ando, T., Ishiguro, H., Kuwabara, Y., Kimura, M., Mitsui, A., Sugito, N., Mori, R., Ogawa, R., Katada, T., & Fujii, Y. (2007) · Diseases of the Esophagus · doi:10.1111/j.1442-2050.2007.00700.x · Cited by 32
Ochiai, T., Nishimura, K., Noguchi, H., Kitajima, M., Tsukada, A., Watanabe, E., Nagaoka, I., & Futagawa, S. (2006) · International Journal of Cancer · doi:10.1002/ijc.21779 · Cited by 31
“Thus, OPRT, together with TS and DPD, is thought to largely associate with the induction of 5-FU antitumor effect.(18,19) In the present study, we retrospectively evaluated the correlation to prognosis among OPRT, DPD and TS, in CRC subjected to 5-FU-based adjuvant chemotherapy.”
BackgroundAlbadari, N. G., Xie, Y., & Li, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1340401 · Cited by 38
Yawata, A., Kim, S.-R., Miyajima, A., Kubo, T., Ishida, S., Saito, Y., Nakajima, Y., Katori, N., Matsumoto, Y., Fukuoka, M., et al. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-1018-z · Cited by 30
“a methyl donor as a rate-limiting step in cancerous tissues [5, 18].”
BackgroundResultCurcumin, calebin A and chemosensitization: How are they linked to colorectal cancer?
Brockmueller, A., Samuel, S. M., Mazuráková, A., Büsselberg, D., Kubatka, P., & Shakibaei, M. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121504 · Cited by 27
Resistance to 5-fluorouracil: The molecular mechanisms of development in colon cancer cells
Radenković, N., Nikodijević, D. D., Jovankić, J. V., Blagojević, S., & Milutinović, M. G. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176979 · Cited by 30
Miyazaki, K., Shibahara, T., Sato, D., Uchida, K., Suzuki, H., Matsui, H., Yanaka, A., Nakahara, A., & Matsuzaki, Y. (2006) · Journal of Gastroenterology · doi:10.1007/s00535-005-1733-6 · Cited by 25
Brody, J. R., Hucl, T., Costantino, C. L., Eshleman, J. R., Gallmeier, E., Zhu, H., van der Heijden, M. S., Winter, J. M., Wikiewicz, A. K., Yeo, C. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3610 · Cited by 25
A rare case of primary choriocarcinoma in the sigmoid colon
Maehira, H. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i39.6683 · Cited by 24
Sakamoto, E., Nagase, H., Kobunai, T., Oie, S., Oka, T., Fukushima, M., & Oka, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.164 · Cited by 23
Kumamoto, K., Kuwabara, K., Tajima, Y., Amano, K., Hatano, S., Ohsawa, T., Okada, N., Ishibashi, K., Haga, N., & Ishida, H. (2012) · Oncology Letters · doi:10.3892/ol.2012.598 · Cited by 22
“Regarding the correlation between TS and OPRT expression, the combination of OPRT with a high expression and TS with a low expression is considered to be effective for chemotherapy (28).”
BackgroundZhang, X., & Diasio, R. B. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.3.257 · Cited by 21
“Fuji and colleagues reported good sensitivity to 5-FU in cancers with high cell proliferation rate, suggesting that DPD is downregulated in such cancers [36].”
BackgroundTaomoto, J., Yoshida, K., Wada, Y., Tanabe, K., Konishi, K., Tahara, H., & Fukushima, M. (2006) · Oncology · doi:10.1159/000098873 · Cited by 18
“decreased expression of the OPRT gene was observed in 5-FU-resistant gastric cancer cells in vitro, and in studies using human colorectal cancer tissues, higher OPRT enzyme activity was observed in 5-FU-sensitive tissues compared to non-sensitive tissues in an in vitro chemosensitivity test [”
ResultIshikawa, M., Miyauchi, T., & Kashiwagi, Y. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-188 · Cited by 18
“Takenoue T, Nagawa H, Matsuda K, Fujii S, Nita ME, Hatano K, Kitayama J, Tsuruo T, Muto T: Relation between Thymidylate Synthase Expression and Survival in Colon Carcinoma, and Determination of Appropriate Application of 5-Fluorouracil by Immunohistochemical Method.”
InfluentialUpregulation of Enzymes Metabolizing 5-Fluorouracil in Colorectal Cancer
Matsusaka, S., Yamasaki, H., Fukushima, M., & Wakabayashi, I. (2006) · Chemotherapy · doi:10.1159/000098249 · Cited by 18
“and expression of OPRT in tumors increases the efficacy of 5-FU against the tumor. In the present study, we measured enzyme activities of OPRT, TP and UP in colorectal cancer tissues and normal tissues and compared their activities. The present study clearly demonstrated that the degree of an increase in OPRT activity…”
ResultLi, J., Xu, X., Han, X., Fang, Y., Shi, C., Jin, D., & Lou, W. (2015) · Pancreas · doi:10.1097/mpa.0000000000000501 · Cited by 17
Choi, I. S., Lee, H. S., Lee, K., Kim, H., Kim, K. H., Kim, Y. J., Kim, J. H., Kim, W. H., & Lee, J. S. (2010) · Medical Oncology · doi:10.1007/s12032-010-9590-4 · Cited by 17
“Some previous studies insisted that a high OPRT level is associated with greater sensitivity to 5-FU [23, 24].”
BackgroundImmunohistochemical Demonstration of Dihydropyrimidine Dehydrogenase in Normal and Cancerous Tissues
Kamoshida, S., Shiogama, K., Matsuoka, H., Matsuyama, A., Shimomura, R., Inada, K.-I., MARUTA, M., & Tsutsumi, Y. (2003) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.36.471 · Cited by 17
Ren, D., Kim, I., Koh, S. B., Chang, S. J., Eom, M., Yi, S. Y., Seong, S. H., Kim, M., Bronner, M. P., & Cho, M. (2009) · Journal of Surgical Oncology · doi:10.1002/jso.21383 · Cited by 14
“However, the prognostic significance of TS expression is influenced by the treatment modality [6,7,12] as well as the method of TS assessment.”
MethodYoshitomi, I., Kawasaki, G., Yanamoto, S., & Mizuno, A. (2006) · Oral Oncology · doi:10.1016/j.oraloncology.2005.12.009 · Cited by 14
Challenge for a better combination with basic evidence
Yoshida, K., Yamaguchi, K., Osada, S., Kawaguchi, Y., Takahashi, T., Sakashita, F., & Tanaka, Y. (2008) · International Journal of Clinical Oncology · doi:10.1007/s10147-008-0793-z · Cited by 12
“demonstrated decreased expression of the OPRT gene was observed in 5-FU-resistant gastric cancer cells in vitro, and in studies using human colorectal cancer tissues, a higher OPRT enzyme activity was observed in 5-FU-sensitive tissues than in nonsensitive tissues in an in vitro chemosensitivity test.(44) Moreover, Ic…”
ResultGhosh, S., Winter, J. M., Patel, K. G., & Kern, S. E. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.8.16867 · Cited by 11
“Orotate phosphoribosyl-transferase (OPRT), the enzyme necessary for stabilization and formation of the ternary complex(39) following 5-FU treatment, is also a potential predictor of 5-FU effects.(27) The G213A polymorphism in OPRT is reported to be associated with grade 3–4 toxicity in response to 5-FU therapy.”
BackgroundAbnormal head posture: an ophthalmological approach.
Caldeira, J. A. F. (2000) · PubMed · Cited by 13
Sakurai, Y., Sakamoto, K., Sugimoto, Y., Yoshida, I., Masui, T., Tonomura, S., Inaba, K., Shoji, M., Nakamura, Y., Uyama, I., et al. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00200.x · Cited by 11
Yasumatsu, R., Nakashima, T., & Komune, S. (2012) · Journal of Oncology · doi:10.1155/2012/649605 · Cited by 10
“To date, OPRT expression in the tumors has been related to the clinical response or survival of cancer patients receiving 5-FU-based chemotherapy [5, 6].”
BackgroundGhosh, S., Hossain, M. Z., Borges, M. W., Goggins, M., Ingersoll, R., Eshleman, J. R., Klein, A. P., & Kern, S. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034426 · Cited by 10
“Orotate phosphoribosyl-transferase (Oprt), the enzyme necessary for stabilization and formation of the ternary complex [41] following 5FU treatment is also a potential predictor of 5FU effects [42].”
BackgroundClinical implications of proliferation activity in T1 or T2 male gastric cancer patients
Kim, Y., Eom, B. W., Kook, M., Kim, H.-S., Kim, M. K., Hwang, H.-L., Chandra, V., Poojan, S., Song, Y., Koh, J.-S., et al. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.79 · Cited by 11
Changes of thymidine kinase (TK) during adjuvant and palliative chemotherapy.
Topolčan, O., Holubec, L., Fínek, J., Stieber, P., Holdenrieder, S., Lamerz, R., Sen., L. H., Svobodová, Š., Visokai, V., & Lipská, L. (2005) · PubMed · Cited by 9
Ochiai, T., Nishimura, K., Noguchi, H., Kitajima, M., Tsuruoka, Y., Takahashi, Y., Tsukada, A., Watanabe, E., Nagaoka, I., & Futagawa, S. (2006) · Journal of Surgical Oncology · doi:10.1002/jso.20553 · Cited by 9
“Along with TS and DPD, OPRT is therefore thought to play an important role in the tumor response to 5FU [5,6].”
BackgroundKawamura, K., Takiguchi, N., Wada, A., Takenobu, H., Kimura, H., Soda, H., Nagata, M., Asano, T., & Tagawa, M. (2006) · PubMed · Cited by 10
Kim, S. Y., Baek, J. Y., Oh, J. H., Park, S. C., Sohn, D. K., Kim, M. J., Chang, H. J., Kong, S., & Kim, D. Y. (2017) · Radiation Oncology · doi:10.1186/s13014-017-0800-5 · Cited by 10
“Clinical activity of 5-FU or UFT was associated with enhanced enzymatic activity or higher expression of UMPS in several studies [21, 22], thus CC genotype harbor a possibility of resulting improved clinical outcome.”
BackgroundDrug Resistance Mechanisms on Colorectal Cancer
Kurter, H., YEŞİL, J., Daşkın, E., Calibasi‐Kocal, G., Ellıdokuz, H., & Başbınar, Y. (2021) · Journal of Basic and Clinical Health Sciences · doi:10.30621/jbachs.869310 · Cited by 8
“In other words, the expression levels of these enzymes are lower in 5-FU resistance cells (18).”
BackgroundYamada, T., Tanaka, N., Yokoi, K., Seya, T., Kanazawa, Y., Koizumi, M., Ohaki, Y., & Tajiri, T. (2008) · Journal of Nippon Medical School · doi:10.1272/jnms.75.23 · Cited by 8
Kamoshida, S., Sakamoto, N., Matsuoka, H., Sakurai, Y., Sakamoto, K., Sugimoto, Y., Fukushima, M., & Tsutsumi, Y. (2005) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.38.69 · Cited by 8
“The combined and reliable immunohistochemical analysis of TS, a target enzyme of 5-FU, and DPD, a 5-FU-degrading enzyme, and OPRT may lead to accurate evaluation of the responsiveness of cancer tissue to 5-FUbased chemotherapy [1, 3, 4, 7, 8].”
BackgroundKugimiya, N., Harada, E., Suehiro, Y., Suga, A., Takemoto, Y., & Hamano, K. (2019) · Oncology Letters · doi:10.3892/ol.2019.10181 · Cited by 7
“On the other hand, it has also been reported that colon cancer patients with high TP expression had a good prognosis after adjuvant chemotherapy (7,22).”
Akagi, Y., Kinugasa, T., Mizobe, T., Kawahara, A., Kage, M., & Shirouzu, K. (2012) · PubMed · Cited by 7
Overexpression of orotate phosphoribosyl transferase in hormone-refractory prostate cancer
Tanaka (1994) · Oncology Reports · doi:10.3892/or_00000186 · Cited by 5
Sumi, T., Katsumata, K., Tsuchida, A., Ishizaki, T., Shimazu, M., & Aoki, T. (2010) · Chemotherapy · doi:10.1159/000313524 · Cited by 5
“Phosphorylation is necessary to activate 5-FU into its nucleotides. Orotate phosphoribosyltransferase (OPRT) is an enzyme that directly converts 5-FU to 5-fluorouridine-5'-monophosphate. Therefore, high levels of intratumoral OPRT enhance the cytotoxicity of 5-FU [ ,”
BackgroundGusella, M., Bertolaso, L., Bolzonella, C., Pasini, F., & Padrini, R. (2011) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2011.0021 · Cited by 5
“Other in vitro reports demonstrated a positive correlation between high basal OPRT activity of human tumor cells and sensitivity to 5-FU, suggesting a potential for predicting the effects of this drug in the clinical setting (Fujii et al., 2003; Isshi et al., 2007).”
Sakurai, Y., Kamoshida, S., Furuta, S., 砂川, 理., Inaba, K., Isogaki, J., Komori, Y., Uyama, I., & Tsutsumi, Y. (2007) · Gastric Cancer · doi:10.1007/s10120-007-0440-9 · Cited by 5
“One possible explanation for this fi nding is that because OPRT is the enzyme related to pyrimidine synthesis in vivo, higher OPRT levels would be expected in tissues with high cell proliferative activity [26].”
BackgroundHozumi, Y., Tanaka, T., Nakano, T., Matsui, H., Nasu, T., Koike, S., Kakehata, S., Ito, T., & Goto, K. (2015) · Biomedical Research · doi:10.2220/biomedres.36.403 · Cited by 5
Takahashi, M., Kawabata, R., KAWANO, A., Murakami, Y., Sutou, Y., Inai, T., Akazawa, S., Hamao, T., Hayashi, H., Fukawa, T., et al. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1997 · Cited by 4
Microdissection is essential for gene expression analysis of irradiated rectal cancer tissues
Kusunoki (2009) · Oncology Reports · doi:10.3892/or_00000515 · Cited by 4
“We selected candidate genes that had previously been shown to be involved in the metabolism of 5-FU (TS, DPD, and OPRT), and TS, DPD, and OPRT, are associated with poor response to 5-FU-based treatment (14-17).”
Iwahashi, S., Shimada, M., Utsunomiya, T., Morine, Y., Imura, S., Ikemoto, T., Mori, H., & Hanaoka, J. (2012) · Surgery Today · doi:10.1007/s00595-012-0118-8 · Cited by 4
“However, some studies found no significant differences between high and low DPD groups [24, 25].”
BackgroundOchiai (2009) · Molecular Medicine Reports · doi:10.3892/mmr_00000113 · Cited by 3
Sanada (1994) · Oncology Reports · doi:10.3892/or_00000102 · Cited by 3
Mechanisms of treatment resistance in colorectal cancer
Mosoane, B., Lolas, G., & Dlamini, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-33475-7.00014-7 · Cited by 3
Mori, R., Tanahashi, T., Yawata, K., Kato, J., Okumura, N., Yamaguchi, K., Futamura, M., & Yoshida, K. (2015) · Translational gastrointestinal cancer · Cited by 2
Tanaka, T. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-163-5_25 · Cited by 2
Tsuzuki, M., Satomi, T., & Chiba, H. (2010) · Oral Medicine & Pathology · doi:10.3353/omp.14.135 · Cited by 1
Bidgoli, S. A., Sepideh, Minaee, Bagher, Ghahremani, Mohammad, H. F., ., D. Z., Mansoor, Ostad, ., S. N., et al. (2005) · International Journal of Pharmacology · doi:10.3923/ijp.2005.104.111 · Cited by 1
Determinants of antifolate and 5-fluorouracil efficacy
Mauritz, R. (2011) · Pure Amsterdam UMC
OPRT Is a Potential Predictive Factor for the Response to S-1 in Gastric Cancer
Li, T., Leong, M., Yuan, J., Li, J., & Chen, L. (2013) · Journal of Cancer Therapy · doi:10.4236/jct.2013.41a015
“have revealed that OPRT enzyme activity is higher in 5-FU-sensitive tissues than in nonsensitive ones using in vitro chemosensitivity tests [29].”
MethodToiyama, Y., Inoue, Y., Hiro, J., Ojima, E., Watanabe, H., Miki, C., & Kusunoki, M. (2008) · Oncology Reports · doi:10.3892/or.19.3.755
Maring, J. G. (2005) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Rabinovitch-Chable, H., Durand, K., Genet, D., Marin, B., Beauvais‐Dzugan, H., Léobon, S., Tubiana-Mathieu, N., Preux, P., Paraf, F., Cook‐Moreau, J., et al. (2006) · PubMed
Yamada, M., Takita, N., Kitajima, M., Kasamaki, S., Sakamoto, K., Ochiai, T., & Kamano, T. (2006) · Nihon Daicho Komonbyo Gakkai Zasshi · doi:10.3862/jcoloproctology.59.113
Takita, N., Kitajima, M., Kitamura, D., Maeda, T., Yamamoto, T., Sakamoto, K., Ochiai, T., & Kamano, T. (2005) · Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) · doi:10.4030/jjcs1979.30.6_836
Ishida, H., Shirakawa, K., Ohsawa, T., Okada, N., Nakada, H., YOKOYAMA, M., Inokuma, S., & Hashimoto, D. (2005) · Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) · doi:10.4030/jjcs1979.30.2_126
Aguiar, S. (2004) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2004.tde-26102005-151553
Unraveling the mystery of treatment resistance in colorectal cancer
Dlamini, Z., Hull, R., & Kaufmann, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-33475-7.00009-3
Ito, T., 修治, 小., KOSHU, H., 隆, 那., 靖弘, 阿., Inamura, H., & Aoyagi, M. (2004) · Toukeibu Gan · doi:10.5981/jjhnc.30.657
Metadata
- Authors
- Fujii, R., Seshimo, A., & Kameoka, S.
- Affiliations
- Tokyo Women's Medical University (JP)
- Corresponding author
- Fujii, R.
- Venue
- International Journal of Clinical Oncology
- Published
- 2003-04-01
- Volume
- 8
- Issue
- 2
- Pages
- 72-78
- ISSN
- 1341-9625 (ISSN-L)
- 1437-7772
- OpenAlex
- W1966603374
- Cited by
- 82
- References
- 25
- Citations by year
- 2024: 5 · 2023: 2 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 1 · 2017: 1 · 2015: 6 · 2014: 1 · 2013: 3 · 2012: 5
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- International Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase, 5-fluorouracil sensitivity, colorectal cancer, Ki-67, drug response prediction
- MeSH terms
- Adenocarcinoma, Adult, Aged, Aged, 80 and over, Biopsy, Needle, Cell Division, Female, Fluorouracil, Humans, Immunohistochemistry, Male, Middle Aged, Neoplasm Staging, Orotate Phosphoribosyltransferase, Oxidoreductases, Probability, Prospective Studies, Sampling Studies, Sensitivity and Specificity, Thymidylate Synthase, Tumor Cells, Cultured, Biomarkers, Tumor, Colorectal Neoplasms, Statistics, Nonparametric, Drug Resistance, Neoplasm, Dihydrouracil Dehydrogenase (NADP)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.